Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
Daniel A. Arber, Attilio Orazi, Robert P. Hasserjian, et al.
Blood (2022) Vol. 140, Iss. 11, pp. 1200-1228
Open Access | Times Cited: 1596

Showing 1-25 of 1596 citing articles:

Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
Hartmut Döhner, Andrew H. Wei, Frederick R. Appelbaum, et al.
Blood (2022) Vol. 140, Iss. 12, pp. 1345-1377
Open Access | Times Cited: 1700
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
Elı́as Campo, Elaine S. Jaffe, James R. Cook, et al.
Blood (2022) Vol. 140, Iss. 11, pp. 1229-1253
Open Access | Times Cited: 921
Acute myeloid leukemia: 2023 update on diagnosis, risk‐stratification, and management
Shai Shimony, Maximilian Stahl, Richard M. Stone
American Journal of Hematology (2023) Vol. 98, Iss. 3, pp. 502-526
Open Access | Times Cited: 212
Acute myeloid leukaemia
Courtney D. DiNardo, Harry P. Erba, Sylvie D. Freeman, et al.
The Lancet (2023) Vol. 401, Iss. 10393, pp. 2073-2086
Open Access | Times Cited: 165
Primary myelofibrosis: 2023 update on diagnosis, risk‐stratification, and management
Ayalew Tefferi
American Journal of Hematology (2023) Vol. 98, Iss. 5, pp. 801-821
Open Access | Times Cited: 160
Prediction of Risk for Myeloid Malignancy in Clonal Hematopoiesis
Lachelle D. Weeks, Abhishek Niroula, Donna Neuberg, et al.
NEJM Evidence (2023) Vol. 2, Iss. 5
Open Access | Times Cited: 155
Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia
Eric J. Duncavage, Adam Bagg, Robert P. Hasserjian, et al.
Blood (2022) Vol. 140, Iss. 21, pp. 2228-2247
Open Access | Times Cited: 138
Recent advances in targeted therapies in acute myeloid leukemia
Rahul S. Bhansali, Keith W. Pratz, Catherine Lai
Journal of Hematology & Oncology (2023) Vol. 16, Iss. 1
Open Access | Times Cited: 114
TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Biology, Current Therapy, and Future Directions
Naval Daver, Abhishek Maiti, Tapan M. Kadia, et al.
Cancer Discovery (2022) Vol. 12, Iss. 11, pp. 2516-2529
Open Access | Times Cited: 92
Myelodysplastic syndromes: 2023 update on diagnosis, risk‐stratification, and management
Guillermo Garcia‐Manero
American Journal of Hematology (2023) Vol. 98, Iss. 8, pp. 1307-1325
Open Access | Times Cited: 87
International Consensus Classification of acute lymphoblastic leukemia/lymphoma
Amy S. Duffield, Charles G. Mullighan, Michael J. Borowitz
Virchows Archiv (2022) Vol. 482, Iss. 1, pp. 11-26
Open Access | Times Cited: 79
A practical approach to curate clonal hematopoiesis of indeterminate potential in human genetic datasets
Caitlyn Vlasschaert, Taralynn Mack, J. Brett Heimlich, et al.
Blood (2023)
Open Access | Times Cited: 79
Genetic basis and molecular profiling in myeloproliferative neoplasms
Damien Luque Paz, Róbert Královics, Radek C. Skoda
Blood (2022) Vol. 141, Iss. 16, pp. 1909-1921
Open Access | Times Cited: 78
Polycythemia vera: 2024 update on diagnosis, risk‐stratification, and management
Ayalew Tefferi, Tiziano Barbui
American Journal of Hematology (2023) Vol. 98, Iss. 9, pp. 1465-1487
Open Access | Times Cited: 72
Myelofibrosis
Francesco Passamonti, Barbara Mora
Blood (2022) Vol. 141, Iss. 16, pp. 1954-1970
Open Access | Times Cited: 69
Real-World Validation of Molecular International Prognostic Scoring System for Myelodysplastic Syndromes
Elisabetta Sauta, Marie Robin, Matteo Bersanelli, et al.
Journal of Clinical Oncology (2023) Vol. 41, Iss. 15, pp. 2827-2842
Open Access | Times Cited: 63
The evolution of acute lymphoblastic leukemia research and therapy at MD Anderson over four decades
Elias Jabbour, Nicholas J. Short, Nitin Jain, et al.
Journal of Hematology & Oncology (2023) Vol. 16, Iss. 1
Open Access | Times Cited: 60
Clonal haematopoiesis and dysregulation of the immune system
Roger Belizaire, Waihay J. Wong, Michelle L. Robinette, et al.
Nature reviews. Immunology (2023) Vol. 23, Iss. 9, pp. 595-610
Closed Access | Times Cited: 56
Systemic mastocytosis in adults: 2023 update on diagnosis, risk stratification and management
Animesh Pardanani
American Journal of Hematology (2023) Vol. 98, Iss. 7, pp. 1097-1116
Open Access | Times Cited: 56
JAK2 V617F allele burden in polycythemia vera: burden of proof
Alison R. Moliterno, Hannah Kaizer, Brandi Reeves
Blood (2023) Vol. 141, Iss. 16, pp. 1934-1942
Open Access | Times Cited: 54
Multiparameter prediction of myeloid neoplasia risk
Muxin Gu, Sruthi Cheloor Kovilakam, William G. Dunn, et al.
Nature Genetics (2023) Vol. 55, Iss. 9, pp. 1523-1530
Open Access | Times Cited: 51
Validation and refinement of the 2022 European LeukemiaNet genetic risk stratification of acute myeloid leukemia
Christian Rausch, Maja Rothenberg‐Thurley, Annika Dufour, et al.
Leukemia (2023) Vol. 37, Iss. 6, pp. 1234-1244
Open Access | Times Cited: 45
Synthetic Data Generation by Artificial Intelligence to Accelerate Research and Precision Medicine in Hematology
Saverio D’Amico, Daniele Dall’Olio, Claudia Sala, et al.
JCO Clinical Cancer Informatics (2023), Iss. 7
Open Access | Times Cited: 43
AML classification in the year 2023: How to avoid a Babylonian confusion of languages
Sandra Huber, Constance Baer, Stephan Hütter, et al.
Leukemia (2023) Vol. 37, Iss. 7, pp. 1413-1420
Open Access | Times Cited: 41
Intensive chemotherapy with or without gemtuzumab ozogamicin in patients with NPM1-mutated acute myeloid leukaemia (AMLSG 09–09): a randomised, open-label, multicentre, phase 3 trial
Hartmut Döhner, Daniela Weber, Julia Krzykalla, et al.
The Lancet Haematology (2023) Vol. 10, Iss. 7, pp. e495-e509
Closed Access | Times Cited: 40
Page 1 - Next Page

Scroll to top